This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Vadadustat for treating anaemia in chronic kidney disease

< Back

Vadadustat for treating anaemia in chronic kidney disease


Renal Disease and Urology

March 2021

Vadadustat is in development for the treatment of anaemia in patients with chronic kidney disease (CKD). Anaemia is a condition where the body has fewer red blood cells (RBC) to carry oxygen throughout the body resulting in a decline in function of the body’s organs and tissues. Symptoms of anaemia in CKD patients include weakness, fatigue, headaches, dizziness and difficulty breathing. Anaemia is common in people with CKD because diseased kidneys produce less erythropoietin (EPO) which is needed to make RBCs. Current treatment for anaemia in CKD involves erythropoietin stimulating agents (ESAs) however, they may result in adverse side-effects so there is a need for safer treatment options.

Vadadustat, (given orally), works by stimulating the pathways that result in more RBC being produced under low oxygen conditions. Under low oxygen conditions, key regulatory proteins known as hypoxia inducible factors (HIFs) activate genes involved in RBC production to increase the number or RBC available in the blood. If licenced, vadadustat will offer an additional treatment option for anaemia in patients with CKD.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts